LEPU BIO-B (02157) Income Statement & Earnings

5.630
-0.010-0.18%

Market Closed Apr 24 16:08 CST

10.16BMarket Cap35.19P/E (TTM)

LEPU BIO-B (02157) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(FY)Dec 31, 2020

Turnover

154.18%934.87M

249.59%465.94M

63.21%367.79M

-13.20%133.28M

1,347.16%225.35M

--153.55M

--15.57M

----

Operating income

154.18%934.87M

249.59%465.94M

63.21%367.79M

-13.20%133.28M

1,347.16%225.35M

153.55M

15.57M

Cost of sales

-19.74%-89.59M

-30.23%-27.4M

-164.61%-74.82M

-265.63%-21.04M

-1,310.32%-28.28M

---5.76M

---2.01M

----

Operating expenses

-19.74%-89.59M

-30.23%-27.4M

-164.61%-74.82M

-265.63%-21.04M

-1,310.32%-28.28M

-5.76M

-2.01M

Gross profit

188.52%845.28M

290.71%438.54M

48.66%292.97M

-24.06%112.24M

1,352.61%197.08M

147.8M

13.57M

Selling expenses

-64.67%-240.33M

-123.52%-97.88M

-237.10%-145.95M

-216.05%-43.79M

-2,375.47%-43.3M

---13.86M

---1.75M

----

Administrative expenses

-24.13%-114.13M

-79.54%-55.38M

-6.10%-91.94M

21.06%-30.84M

37.58%-86.66M

53.88%-39.07M

11.14%-138.83M

---84.73M

-66.64%-156.24M

51.05%-93.76M

Research and development expenses

8.45%-400.71M

6.63%-202.24M

4.45%-437.7M

6.58%-216.61M

12.63%-458.07M

-0.51%-231.87M

33.74%-524.29M

---230.71M

-123.24%-791.21M

-54.64%-354.43M

Revaluation surplus

-715.50%-31.25M

-13,575.00%-16.96M

-97.10%5.08M

-100.70%-124K

378.55%174.98M

129.18%17.74M

17.66%-62.82M

---60.78M

2.19%-76.29M

-103.57%-77.99M

-Changes in the fair value of financial assets

----

---60.78M

----

-103.57%-77.99M

-Changes in the fair value of other assets

-715.50%-31.25M

-13,575.00%-16.96M

-97.10%5.08M

-100.70%-124K

378.55%174.98M

--17.74M

17.66%-62.82M

----

---76.29M

----

Special items of operating profit

1,811.44%226.27M

-370.53%-23.1M

-105.99%-13.22M

-486.61%-4.91M

2,192.30%220.77M

-76.98%1.27M

-31.68%9.63M

--5.52M

142.03%14.1M

32.21%5.82M

Operating profit

172.97%285.13M

123.35%42.98M

-8,247.73%-390.77M

-55.97%-184.04M

100.68%4.8M

68.17%-118M

30.22%-704.48M

-370.7M

-94.03%-1.01B

-14.45%-520.35M

Financing income

105.60%12.33M

190.90%7.48M

-27.42%6M

-53.48%2.57M

-82.01%8.26M

-84.96%5.53M

1,008.35%45.92M

--36.75M

-21.92%4.14M

1,236.52%5.31M

Financing cost

-27.51%-29.31M

-76.34%-14.93M

-43.50%-22.99M

-6.65%-8.47M

-85.23%-16.02M

-184.48%-7.94M

-52.21%-8.65M

---2.79M

93.42%-5.68M

-64.23%-86.32M

Special items of earning before tax

54.30%-7.51M

11.41%-6.23M

39.87%-16.44M

67.27%-7.04M

15.17%-27.34M

-84.67%-21.5M

-82.15%-32.23M

---11.64M

-46.43%-17.7M

-39.30%-12.08M

Earning before tax

161.44%260.64M

114.88%29.3M

-1,299.93%-424.19M

-38.80%-196.97M

95.67%-30.3M

59.27%-141.9M

32.02%-699.44M

-348.37M

-67.72%-1.03B

-19.00%-613.45M

Tax

---1.75M

----

After-tax profit from continuing operations

161.03%258.89M

114.88%29.3M

-1,299.93%-424.19M

-38.80%-196.97M

95.67%-30.3M

59.27%-141.9M

32.02%-699.44M

-348.37M

-67.72%-1.03B

-19.00%-613.45M

Earning after tax

161.03%258.89M

114.88%29.3M

-1,299.93%-424.19M

-38.80%-196.97M

95.67%-30.3M

59.27%-141.9M

32.02%-699.44M

-348.37M

-67.72%-1.03B

-19.00%-613.45M

Minority profit

80.67%-2.48M

-174.32%-12.44M

-56.21%-12.82M

---4.54M

21.02%-8.21M

----

41.87%-10.39M

---4.09M

43.44%-17.87M

53.84%-31.6M

Profit attributable to shareholders

163.53%261.36M

121.69%41.75M

-1,761.77%-411.38M

-35.61%-192.43M

96.79%-22.1M

58.78%-141.9M

31.84%-689.05M

-344.29M

-73.76%-1.01B

-30.16%-581.85M

Basic earnings per share

162.50%0.15

116.67%0.02

-2,300.00%-0.24

-33.33%-0.12

97.62%-0.01

57.14%-0.09

36.36%-0.42

-0.21

-29.41%-0.66

26.09%-0.51

Diluted earnings per share

162.50%0.15

116.67%0.02

-2,300.00%-0.24

-33.33%-0.12

97.62%-0.01

57.14%-0.09

36.36%-0.42

-0.21

-29.41%-0.66

26.09%-0.51

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

PwC

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(FY)Dec 31, 2020
Turnover	154.18%934.87M	249.59%465.94M	63.21%367.79M	-13.20%133.28M	1,347.16%225.35M	--153.55M	--15.57M	----	----	----
Operating income	154.18%934.87M	249.59%465.94M	63.21%367.79M	-13.20%133.28M	1,347.16%225.35M	153.55M	15.57M
Cost of sales	-19.74%-89.59M	-30.23%-27.4M	-164.61%-74.82M	-265.63%-21.04M	-1,310.32%-28.28M	---5.76M	---2.01M	----	----	----
Operating expenses	-19.74%-89.59M	-30.23%-27.4M	-164.61%-74.82M	-265.63%-21.04M	-1,310.32%-28.28M	-5.76M	-2.01M
Gross profit	188.52%845.28M	290.71%438.54M	48.66%292.97M	-24.06%112.24M	1,352.61%197.08M	147.8M	13.57M
Selling expenses	-64.67%-240.33M	-123.52%-97.88M	-237.10%-145.95M	-216.05%-43.79M	-2,375.47%-43.3M	---13.86M	---1.75M	----	----	----
Administrative expenses	-24.13%-114.13M	-79.54%-55.38M	-6.10%-91.94M	21.06%-30.84M	37.58%-86.66M	53.88%-39.07M	11.14%-138.83M	---84.73M	-66.64%-156.24M	51.05%-93.76M
Research and development expenses	8.45%-400.71M	6.63%-202.24M	4.45%-437.7M	6.58%-216.61M	12.63%-458.07M	-0.51%-231.87M	33.74%-524.29M	---230.71M	-123.24%-791.21M	-54.64%-354.43M
Revaluation surplus	-715.50%-31.25M	-13,575.00%-16.96M	-97.10%5.08M	-100.70%-124K	378.55%174.98M	129.18%17.74M	17.66%-62.82M	---60.78M	2.19%-76.29M	-103.57%-77.99M
-Changes in the fair value of financial assets	----	----	----	----	----	----	----	---60.78M	----	-103.57%-77.99M
-Changes in the fair value of other assets	-715.50%-31.25M	-13,575.00%-16.96M	-97.10%5.08M	-100.70%-124K	378.55%174.98M	--17.74M	17.66%-62.82M	----	---76.29M	----
Special items of operating profit	1,811.44%226.27M	-370.53%-23.1M	-105.99%-13.22M	-486.61%-4.91M	2,192.30%220.77M	-76.98%1.27M	-31.68%9.63M	--5.52M	142.03%14.1M	32.21%5.82M
Operating profit	172.97%285.13M	123.35%42.98M	-8,247.73%-390.77M	-55.97%-184.04M	100.68%4.8M	68.17%-118M	30.22%-704.48M	-370.7M	-94.03%-1.01B	-14.45%-520.35M
Financing income	105.60%12.33M	190.90%7.48M	-27.42%6M	-53.48%2.57M	-82.01%8.26M	-84.96%5.53M	1,008.35%45.92M	--36.75M	-21.92%4.14M	1,236.52%5.31M
Financing cost	-27.51%-29.31M	-76.34%-14.93M	-43.50%-22.99M	-6.65%-8.47M	-85.23%-16.02M	-184.48%-7.94M	-52.21%-8.65M	---2.79M	93.42%-5.68M	-64.23%-86.32M
Special items of earning before tax	54.30%-7.51M	11.41%-6.23M	39.87%-16.44M	67.27%-7.04M	15.17%-27.34M	-84.67%-21.5M	-82.15%-32.23M	---11.64M	-46.43%-17.7M	-39.30%-12.08M
Earning before tax	161.44%260.64M	114.88%29.3M	-1,299.93%-424.19M	-38.80%-196.97M	95.67%-30.3M	59.27%-141.9M	32.02%-699.44M	-348.37M	-67.72%-1.03B	-19.00%-613.45M
Tax	---1.75M	----	----	----	----	----	----	----	----	----
After-tax profit from continuing operations	161.03%258.89M	114.88%29.3M	-1,299.93%-424.19M	-38.80%-196.97M	95.67%-30.3M	59.27%-141.9M	32.02%-699.44M	-348.37M	-67.72%-1.03B	-19.00%-613.45M
Earning after tax	161.03%258.89M	114.88%29.3M	-1,299.93%-424.19M	-38.80%-196.97M	95.67%-30.3M	59.27%-141.9M	32.02%-699.44M	-348.37M	-67.72%-1.03B	-19.00%-613.45M
Minority profit	80.67%-2.48M	-174.32%-12.44M	-56.21%-12.82M	---4.54M	21.02%-8.21M	----	41.87%-10.39M	---4.09M	43.44%-17.87M	53.84%-31.6M
Profit attributable to shareholders	163.53%261.36M	121.69%41.75M	-1,761.77%-411.38M	-35.61%-192.43M	96.79%-22.1M	58.78%-141.9M	31.84%-689.05M	-344.29M	-73.76%-1.01B	-30.16%-581.85M
Basic earnings per share	162.50%0.15	116.67%0.02	-2,300.00%-0.24	-33.33%-0.12	97.62%-0.01	57.14%-0.09	36.36%-0.42	-0.21	-29.41%-0.66	26.09%-0.51
Diluted earnings per share	162.50%0.15	116.67%0.02	-2,300.00%-0.24	-33.33%-0.12	97.62%-0.01	57.14%-0.09	36.36%-0.42	-0.21	-29.41%-0.66	26.09%-0.51
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion
Auditor	Ernst & Young	--	Ernst & Young	--	PwC	--	PwC	--	PwC	PwC

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"